Ibio (IBIO) AI Stock Analysis

• Market Cap: $75.65M
• Dividend Yield: N/A
• Average Volume (3M): 1.07M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.52
• Revenue Growth: 185.71%
• EPS Growth: 79.03%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.09
• Shares Outstanding: 34,543,560
• 10 Day Avg. Volume: 927,622
• 30 Day Avg. Volume: 1,069,551
• PEG Ratio: <0.01
• Price to Book (P/B): 0.54
• Price to Sales (P/S): 20.03
• P/FCF Ratio: -0.52
• Enterprise Value/Market Cap: 0.11
• Enterprise Value/Revenue: 28.44
• Enterprise Value/Gross Profit: -37.10
• Enterprise Value/Ebitda: -0.40
• 1Y Price Target: $5.50
• Price Target Upside: 151.14% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -0.29
• Revenue Forecast (FY): $200.00K

• Rating: 51 Neutral
• Price Target: $2.50 ▲(14.16% Upside)
• Action: Reiterated Date: 03/10/26
• Date: Action: Reiterated 03/10/26

The score is held down primarily by weak financial performance (minimal revenue, deep losses, and significant cash burn). Technicals provide moderate support with a constructive longer-term trend and neutral momentum, while corporate events are mixed but include a positive pipeline update and funding to extend runway. Valuation is constrained by ongoing losses and the lack of a dividend yield.

Positive Factors

Differentiated Pipeline Signal

IBIO-610’s NHP body-composition signal and reported long half-life reinforce a potentially differentiated, fat‑selective obesity/cardiometabolic asset. A long dosing interval and a first‑in‑class profile materially strengthen strategic partnering and licensing optionality across development timelines.

Secured Near-Term Funding

The ~$26M institutional private placement explicitly earmarked for pipeline advancement extends runway into 2028, lowering near‑term financing pressure. That funding materially increases the company’s ability to reach key preclinical and early clinical milestones without immediate dilutive shelf taps.

Low Leverage

Markedly lower debt provides structural financial flexibility: minimal interest burden and greater capacity to deploy capital to R&D or partnerships. Low leverage reduces refinancing risk and preserves optionality while the company pursues development milestones.

Negative Factors

Minimal Commercial Revenue

Extremely limited and declining revenue signals lack of commercial scale and recurring cash inflows. With negligible product sales, the business remains development‑stage and dependent on external capital to fund operations and progress programs, raising execution risk over the medium term.

High Cash Burn

Persistent negative OCF and FCF mean the company must routinely access capital markets or partners to fund development. This structural cash burn increases dilution risk, creates dependency on continued financing availability, and limits internal flexibility to scale programs without external support.

Limited Internal Capacity

A very small employee base constrains internal drug development, regulatory, and commercialization capabilities. Progressing multiple preclinical programs will likely require external CROs, consultants, or partners, increasing execution complexity and reliance on third parties for durable program advancement.

Ibio Business Overview & Revenue Model

Company Description

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

How the Company Makes Money

Ibio generates revenue through a combination of product sales, research and development collaborations, and licensing agreements. The company partners with other biotech firms and academic institutions to co-develop its products, sharing in the financial benefits of successful outcomes. Additionally, Ibio may receive upfront payments, milestone payments, and royalties from its partners based on the sales of products developed using its technology. The revenue model is further supported by grants and contracts, particularly for vaccine development and other projects that align with public health initiatives.

Ibio Financial Statement Overview

Summary

Very limited revenue scale and steep decline (TTM revenue ~$0.3M, down ~40%) with deeply negative profitability (EBIT margin ~-52%, net margin ~-82%). While leverage is now low (debt-to-equity ~0.04), operating and free cash flow remain materially negative (OCF ~-$18.6M; FCF ~-$19.2M), keeping overall financial strength weak.

Income Statement

TTM (Trailing-Twelve-Months) revenue is very small ($0.3M) and fell sharply (-40%), while profitability remains deeply negative (EBIT margin around -52% and net margin around -82%). Although losses have improved versus some prior periods (notably the 2023 net loss), the overall picture is still one of limited commercial scale and persistent operating losses.

Balance Sheet

Leverage has improved meaningfully over time, with low debt relative to equity in TTM (debt-to-equity ~0.04) versus much higher levels in 2023. That said, returns remain very weak (TTM return on equity is materially negative), reflecting ongoing losses that continue to erode shareholder value despite the lighter debt load.

Cash Flow

Cash burn remains substantial in TTM, with negative operating cash flow (~-$18.6M) and negative free cash flow (~-$19.2M). Free cash flow has improved versus some prior periods (positive growth rate), but cash generation is still not self-sustaining and remains tightly linked to continued losses (free cash flow roughly tracks net income).

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	300.00K	400.00K	225.00K	0.00	1.88M	2.37M
Gross Profit	-230.00K	400.00K	225.00K	0.00	-1.91M	909.00K
EBITDA	-21.46M	-17.04M	-14.02M	-27.85M	-25.72M	-28.55M
Net Income	-24.74M	-18.38M	-24.91M	-65.01M	-50.39M	-23.21M
Balance Sheet
Total Assets	64.39M	23.18M	28.73M	41.21M	99.41M	146.97M
Cash, Cash Equivalents and Short-Term Investments	52.70M	8.58M	14.21M	7.33M	33.52M	96.97M
Total Debt	2.45M	3.51M	4.46M	17.07M	25.77M	32.72M
Total Liabilities	7.83M	8.30M	7.41M	25.83M	35.92M	38.40M
Stockholders Equity	56.56M	14.88M	21.32M	15.38M	63.48M	108.58M
Cash Flow
Free Cash Flow	-19.19M	-15.32M	-18.76M	-36.17M	-45.13M	-35.23M
Operating Cash Flow	-18.63M	-15.30M	-18.55M	-30.44M	-37.80M	-30.06M
Investing Cash Flow	-24.45M	742.00K	906.00K	7.01M	-5.13M	-26.48M
Financing Cash Flow	64.73M	8.93M	24.49M	2.30M	-5.80M	78.83M

Ibio Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.19
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IBIO, the sentiment is Neutral. The current price of 2.19 is below the 20-day moving average (MA) of 2.56, below the 50-day MA of 2.40, and above the 200-day MA of 1.39, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 41.06 is Neutral, neither overbought nor oversold. The STOCH value of 15.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IBIO.

Ibio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IBIO	51 Neutral	$75.65M	-5.32	-71.26%	―	185.71%	79.03%
NERV	49 Neutral	$336.67M	-0.12	―	―	―	-323.61%
FBLG	44 Neutral	$17.75M	-0.54	-1292.87%	―	―	18.47%
PULM	43 Neutral	$7.56M	-1.58	-79.47%	―	-99.97%	35.59%
CMMB	39 Underperform	$12.31M	-2.33	-89.92%	―	―	53.19%

Ibio Corporate Events

iBio Highlights IBIO-610 Obesity and Cardiometabolic Potential

On March 9, 2026, iBio reported preclinical body composition data from an obese non-human primate study of IBIO-610, a potential first-in-class Activin E antibody for fat-selective weight loss and related cardiometabolic conditions. In this small, not statistically powered study, two once-every-eight-week doses of IBIO-610 cut visceral fat by 6.7% and total fat mass by 5.2% versus vehicle, with only a slight increase in lean mass, mirroring earlier rodent findings and results seen by others targeting the Activin E pathway in humans.

The company said previously disclosed data from the same study showed IBIO-610 has an extended half-life of 33.2 days in obese primates, supporting projections of up to twice-yearly dosing in humans and underlining its bid to position the drug as a differentiated obesity and cardiometabolic therapy. Alongside the obesity program, iBio also updated its corporate presentation to highlight a strategic push into the cardiopulmonary arena, including pulmonary hypertension in heart failure with preserved ejection fraction, using its myostatin x Activin A bispecific antibody platform as a potential next-generation treatment approach.

The most recent analyst rating on (IBIO) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.

Ibio Ends At-The-Market Equity Offering Program

On February 23, 2026, Ibio terminated its At Market Issuance Sales Agreement with Chardan Capital Markets LLC and Craig-Hallum Capital Group LLC, which had been in place since July 3, 2024. As a result, the company also ended its at-the-market program to sell up to $7.35 million of common stock under a July 3, 2024 prospectus, and confirmed that no further offerings or sales will occur under that agreement or prospectus.

The termination of the at-the-market facility means Ibio will no longer use this particular equity issuance mechanism for incremental capital, signaling a shift in its funding strategy or capital markets approach. The move may affect the company’s near-term flexibility to tap public markets for small, continuous share sales and could prompt investors to watch for alternative financing arrangements or updated capital plans.

The most recent analyst rating on (IBIO) stock is a Sell with a $2.50 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.

iBio Announces Private Placement to Fund Pipeline Expansion

On January 8, 2026, iBio, Inc. entered into a securities purchase agreement with existing, healthcare-focused institutional investors for an at-the-market private placement of 1,408,481 common shares and pre-funded warrants to purchase up to 9,653,257 additional shares, at a price of $2.35 per share (or $2.349 per pre-funded warrant). The transaction, led by Frazier Life Sciences with Leerink Partners as lead placement agent and LifeSci Capital and Oppenheimer & Co. as co-placement agents, is expected to close on or about January 13, 2026 and generate approximately $26 million in gross proceeds. The funding is earmarked to advance iBio’s preclinical cardiometabolic pipeline, including IBIO-610, IBIO-600 and its myostatin and activin A bispecific programs, as well as other preclinical assets and general corporate purposes, and is expected to extend the company’s cash runway into calendar 2028; the deal also includes customary beneficial-ownership caps on warrant exercises and registration rights obligating iBio to register the resale of the newly issued securities.

The most recent analyst rating on (IBIO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.